(Q36164122)

12 August 2017

1 reference

title

The immunobiology of Guillain-Barré syndromes (English)

1 reference

12 August 2017

Guillain–Barré syndrome

0 references

author name string

Hugh J Willison

series ordinal

1

1 reference

12 August 2017

1 June 2005

1 reference

Journal of the Peripheral Nervous System

12 August 2017

1 reference

12 August 2017

10

1 reference

12 August 2017

2

1 reference

12 August 2017

94-112

1 reference

Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Large-scale in vivo synthesis of the carbohydrate moieties of gangliosides GM1 and GM2 by metabolically engineered Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Glial cells and neurotransmission: an inclusive view of synaptic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

CD1: antigen presentation and T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The regulation of self-reactive B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

T-Independent immune response: new aspects of B cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Serum IgG antibodies to P0 dimer and 35 kDa P0 related protein in neuropathy associated with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Tolerance induction in clinical transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Induction of experimental autoimmune neuritis with peripheral myelin protein-22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Immune response, accommodation, and tolerance to transplantation carbohydrate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The relationship of neuromuscular synapse elimination to synaptic degeneration and pathology: insights from WldS and other mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Localization of major gangliosides in the PNS: implications for immune neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Cell biology. Integrins, rafts, Rac, and Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Lipid rafts act as specialized domains for tetanus toxin binding and internalization into neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Serum antibodies to gangliosides in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Major histocompatibility complex class II association and induction of T cell responses by carbohydrates and glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Haemophilus influenzae as a possible cause of Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Ganglioside complexes as new target antigens in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Combinatorial ganglioside biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Experimental sensory neuropathy induced by sensitization with ganglioside GD1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The refractory period of transmission is impaired in axonal Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Ganglioside structures and distribution: Are they localized at the nerve ending?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Gangliosides: structure, isolation, and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Acute ophthalmoparesis in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Activity alters muscle reinnervation and terminal sprouting by reducing the number of Schwann cell pathways that grow to link synaptic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Complement regulation at the molecular level: The structure of decay-accelerating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Glycobiology of the neuromuscular junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Ganglioside rafts as MAG receptors that mediate blockade of axon growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The possibilities and pitfalls for anti-complement therapies in inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Characterization of anti-ganglioside antibodies present in normal human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Interaction of botulinum and tetanus toxins with the lipid bilayer surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Sialosyl-galactose: a common denominator of Guillain-Barré and related disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Complement therapeutics; history and current progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Anti-GQ1b IgG antibody syndrome: clinical and immunological range

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Gangliosides and glycosphingolipids of peripheral nervous system myelins--a minireview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Anti-GQ1b ganglioside antibody in peripheral nervous system disorders: pathophysiologic role and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Nontransgenic Hyperexpression of a Complement Regulator in Donor Kidney Modulates Transplant Ischemia/Reperfusion Damage, Acute Rejection, and Chronic Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Glial cells maintain synaptic structure and function and promote development of the neuromuscular junction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Multifocal motor neuropathy human sera block distal motor nerve conduction in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Biosynthesis and degradation of mammalian glycosphingolipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Membrane-targeted complement inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Neurophysiological and immunohistochemical studies on Guillain-Barre syndrome with IgG anti-GalNAc-GD1a antibodies-effects on neuromuscular transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Effect of rabbit anti-asialo-GM1 (GA1) polyclonal antibodies on neuromuscular transmission and acetylcholine-induced action potentials: neurophysiological and immunohistochemical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Elimination of anti-Gal B cells by alpha-Gal ricin1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The regulation of the complement system: insights from genetically-engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Antiglycolipid antibodies, immunoglobulins and paraproteins in motor neuron disease: a population based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The immunopathogenesis of Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Peripheral neuropathies and anti-glycolipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Naive and memory B cells in T-cell-dependent and T-independent responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Acute motor axonal neuropathy: An antibody-mediated attack on axolemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Patterns of recovery in the Guillain-Barre syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

Physiologic-pathologic correlation in Guillain-Barre syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010202.X

10.1111/J.1085-9489.2005.0010202.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15958123